FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

actemra
(tocilizumab)
Genentech, Inc.
Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome, and COVID-19 in hospitalized adults receiving systemic corticosteroids.
avtozma
(tocilizumab)
CELLTRION USA, Inc.
Usage: AVTOZMA® (tocilizumab-anoh) is indicated for adults with moderately to severely active rheumatoid arthritis, giant cell arteritis, and hospitalized adults with COVID-19. It also treats active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.
kevzara
(sarilumab)
sanofi-aventis U.S. LLC
Usage: KEVZARA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and polymyalgia rheumatica who have had inadequate responses to DMARDs or corticosteroids. It is also indicated for active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more.
tocilizumab-anoh
(tocilizumab)
CELLTRION USA, Inc.
Usage: Tocilizumab-anoh is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis (ages 2+), and COVID-19 in hospitalized adults requiring respiratory support while on systemic corticosteroids.
tofidence
(TOCILIZUMAB)
Biogen Inc.
Usage: TOFIDENCE™ (tocilizumab-bavi) is indicated for treating moderately to severely active rheumatoid arthritis in adults who have not responded adequately to DMARDs, as well as active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.
tyenne
(Tocilizumab-aazg)
Fresenius Kabi USA, LLC
Usage: TYENNE® (tocilizumab-aazg) is indicated for treating moderately to severely active rheumatoid arthritis in adults with inadequate response to DMARDs, giant cell arteritis in adults, and active polyarticular or systemic juvenile idiopathic arthritis in patients aged 2 years and older.

Interleukin-6 Receptor Antagonist class drugs

actemra

avtozma

kevzara

tocilizumab-anoh

tofidence

tyenne